Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Total 13F shares
-
45,357,348
-
Share change
-
-1,253,787
-
Total reported value
-
$97,515,460
-
Put/Call ratio
-
3700%
-
Price per share
-
$2.15
-
Number of holders
-
55
-
Value change
-
-$1,939,928
-
Number of buys
-
23
-
Number of sells
-
30
Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q2 2023
As of 30 Jun 2023 ADC Therapeutics SA - Common Shares (ADCT) had 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 45,357,348 shares of stock of the company.
Largest 10 holders included Redmile Group, LLC, Prosight Management, LP, Sio Capital Management, LLC, CITADEL ADVISORS LLC, JPMORGAN CHASE & CO, BANK OF AMERICA CORP /DE/, Frazier Life Sciences Management, L.P., MILLENNIUM MANAGEMENT LLC, PICTET ASSET MANAGEMENT SA, and PRICE T ROWE ASSOCIATES INC /MD/.
This table shows 55 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.